When Mounjaro arrived in the UK in 2024, as a weekly injection that could help with both type 2 diabetes and weight loss, it quickly became one of the most talked-about medicines of the decade. But now, just a year later, the Mounjaro price increase is set to hit, and patients paying privately will feel it the most.
From 1 September 2025, Eli Lilly will raise Mounjaro’s private prices in the UK by as much as 170%. For those on the higher doses, the monthly bill will jump from around £122 to £330.
Mounjaro Price Hike UK
Eli Lilly will raise private prescription prices by up to 170%. The highest monthly dose (15 mg) will rise from around £122 to £330, while lower doses will also see sharp increases:
Mounjaro dose strengths (mg) | Current UK Private Price | New Private Price (From Sept 1, 2025) | Percentage Increase % |
2.5 mg | £92 | £133 | +45% |
5 mg | £92 | £180 | +96% |
7.5 mg and 10 mg | £107 | £255 | +138% |
12.5 mg and 15 mg | £122 | £330 | +170% |
Note: These are official list prices. Private patients may face additional costs once pharmacy consultation and dispensing fees are included.
Why Is This Happening?
- Global price alignment
When Mounjaro entered the UK market, prices were kept low to encourage access and avoid delays in NHS approval. Lilly has now urged that UK costs must align with international markets.
- Donald Trump’s demands on drugmakers
The political pressure has caused to raise European prices so that Americans are not subsidising cheaper global access have played a part. This Mounjaro price hike UK is partly a response to such pressure.
- Rising demand
The global surge in demand for Mounjaro has made it one of the fastest-selling medicines, leading to Lilly’s decision to revise pricing.
Who Will Be Affected by the Increase?
- Private patients
Anyone paying out of pocket via online pharmacies, private providers, or other telehealth platforms will face the full rise in Mounjaro.
- NHS patients
NHS is not affected. Those prescribed through NHS diabetes or weight management pathways will still pay only the standard prescription fee.
This divide means affordability is now a pressing issue for many private patients.
Mounjaro Stockpiling & Shortage Concerns
With the increase in prices, reports of Mounjaro stockpiling have surfaced. Individuals are trying to buy extra pens before the Mounjaro price freeze ends in September. Pharmacists warn this could cause a Mounjaro shortage UK issues during August 2025.
Stockpiling concerns include:
- Risk of supply chain issues and delays for other patients.
- Unsafe use if doses are stored incorrectly.
- A potential rise in the black market weight loss drugs UK, as counterfeit suppliers take advantage of the price hike.
Eli Lilly has not confirmed formal restrictions but is working with providers to monitor supply.
Alternative Weight Loss Treatments UK
For patients struggling with affordability, there are options:
- Wegovy vs Mounjaro UK price
Wegovy may be cheaper and more available for some, though supply shortages have also been reported.
- Alternative weight loss treatments UK
NHS lifestyle support programmes, dietician referrals, or other medical interventions.
The future of Mounjaro supply in the UK remains uncertain, but the 2025 price rise sets a precedent: breakthrough medicines can transform lives, but global politics and corporate strategies shape their affordability.
Final Thoughts
If you use Mounjaro privately, the changes to Mounjaro pricing will affect patients trying to manage their health and well-being. With higher private costs coming into force from September 2025, it’s essential to plan your next steps carefully. Speak to your clinician about alternatives like Wegovy, check whether you may qualify for NHS treatment, and most importantly, only source your medicines from trusted, GPhC-registered UK pharmacies.
At Batley Pharmacy, we’re here to provide clear advice with in-person consultations and safe access to regulated treatments, helping you make informed decisions during this period of change.
FAQs
Depending on the dose, prices will rise between 45% and 170%. The highest dose (15 mg) will cost around £330 per month.
Stockpiling can cause supply shortages, unsafe storage, and even encourage the black market. Patients are urged to order responsibly to protect access for everyone.
Eli Lilly has introduced programmes and is working with UK providers to smooth the transition, though private patients will still face higher costs.
No. NHS patients remain fully unaffected under Lilly’s fixed-price deal and will continue paying only the standard prescription charge.
Eli Lilly says the move aligns UK prices with global markets. Originally, UK pricing was kept low to accelerate NHS access.
Trump has pushed drugmakers to raise European prices, arguing that Americans should not bear higher costs while Europe pays less. Lilly’s UK price hike reflects this political pressure.
Yes. NHS agreements are unaffected, and the old pricing structure remains in place for public prescriptions.
Yes. Private patients will face the rise in pricing, with consultation and dispensing fees potentially raising total monthly costs even further.
